Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery

Original title: Drug-Eluting Balloon for Treatment of Superficial Femoral Artery In-Stent Restenosis Reference: Eugenio Stabile et al. Journal of the American College of Cardiology 60:1739–42 (2012)

Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery 

This prospective registry included 39 patients who received Paclitaxel-Eluting Balloon Angioplasty, (IN.PACT, Medtronic, Minneapolis, Minnesota), for in-stent restenosis in the superficial femoral artery. The average length treated was 82.9 + / – 78.9 mm, this required the use of two eluting balloons per patient. The distal protection filter type was used in all cases. Procedure was successful in all patients. At one year follow-up, 92.1% were free of claudication and there was an absence of restenosis by Doppler.

Conclusion: 

Pharmacological balloons are effective in treating in-stent restenosis in the superficial femoral artery.

Editorial comment

This study, which has a lack of control group limit and a small number of patients, shows encouraging results that should be confirmed by randomized studies against the conventional balloon. Particularly striking was the use of a distal protection filter which added to the cost of eluting balloons, making it very difficult to use in practice.

Dr. Gustavo Hidalgo

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Treatment of Atrial Functional Mitral Regurgitation

Atrial functional mitral regurgitation (aFMR), which results from atrial dilation without significant left ventricular dysfunction, accounts for approximately one-third of mitral regurgitation (MR) cases...

ACURATE Neo2 Underexpansion: Prevalence and Clinical Implications

While transcatheter aortic valve replacement (TAVR) provides durable clinical benefits across a wide range of patients, technical challenges remain that may affect long-term outcomes....

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...